Table 3.
Univariate analysis of Alaska Native gastric cancer patients to identify variables associated with overall survival
| HR1 | 95%CI | P2 value | |
| Age, ≥ 55 yr vs < 55 yr | 0.73 | 0.49-1.07 | 0.11 |
| Sex, male vs female | 0.86 | 0.59-1.27 | 0.45 |
| Geographical Region | 0.53 | ||
| North | 1.00 | ||
| Interior | 0.99 | 0.50-1.96 | |
| Southwest | 0.68 | 0.42-1.11 | |
| Southcentral | 1.00 | 0.61-1.62 | |
| Southeast | 0.65 | 0.15-2.69 | |
| Signet ring, present or absent | 0.78 | 0.52-1.17 | 0.22 |
| Diffuse vs intestinal | 1.01 | 0.68-1.49 | 0.97 |
| Anatomic site | 0.07 | ||
| Noncardia Cardia | 1.00 | ||
| Cardia3 | 1.10 | 0.66-1.84 | |
| Overlap/NOS | 1.74 | 1.08-2.81 | |
| Grade | 0.22 | ||
| Poorly differentiated | 1.00 | ||
| Well/moderately | 0.70 | 0.66-1.84 | |
| Unknown | 0.82 | 0.37-1.84 | |
| AJCC Stage | < 0.0001 | ||
| I | 1.00 | ||
| II | 1.42 | 0.74-2.75 | |
| III | 1.67 | 0.79-3.54 | |
| IV | 4.91 | 2.80-8.61 | |
| Treatment4 | < 0.0001 | ||
| Chemo | 1.00 | ||
| None | 2.07 | 1.29-3.32 | |
| Neoadjuvant, surgery | 0.23 | 0.12-0.45 | |
| Surgery only | 0.29 | 0.14-0.61 | |
| Surgery, adjuvant | 0.27 | 0.13-0.59 | |
| Neoadjuvant, surgery, adjuvant | 0.15 | 0.06-0.39 | |
| No. of nodes examined, ≥ 15 vs < 155 nodes3 | 0.37 | 0.19-0.75 | < 0.0001 |
| Blood Type | 0.04 | ||
| A+ | 1.00 | ||
| AB+ | 0.88 | 0.42-1.82 | |
| B+ | 1.72 | 0.76-3.96 | |
| O+ | 1.78 | 1.05-3.01 | |
| Unknown | 2.35 | 1.24-4.45 | |
| Multiple primaries, yes vs no | 0.73 | 0.45-1.17 | 0.22 |
| Tobacco | 0.51 | ||
| Yes | 1.00 | ||
| None | 0.83 | 0.49-1.42 | |
| Chew/Iqmik | 0.78 | 0.31-1.95 | |
| Former user6 | 1.26 | 0.80-1.97 | |
| Gastric ulcer, yes vs no | 1.02 | 0.67-1.54 | 0.93 |
| Chronic Gastritis, yes vs no | 0.62 | 0.39-0.98 | 0.04 |
| H. pylori, tumor positive vs negative | 0.90 | 0.61-1.34 | 0.62 |
| GERD, yes vs no | 0.75 | 0.51-1.13 | 0.17 |
1
Univariate analysis was performed using Kaplan-Meier analysis model and log-rank test;
2
Bold type indicates statistical significance (P < 0.05);
3
Cardia includes gastroesophageal junction and cardia gastric cancers;
4
Neoadjuvant and adjuvant treatments include chemotherapy and chemoradiation regimens based on NCCN guidelines;
5
Patients that had a resection were included in analysis;
6
Patients discontinued smoking before time of diagnosis. HR: Hazard ratio; CI: Confidence interval; AJCC: American Joint Committee on Cancer; Chemo: Chemotherapy; H. pylori: Helicobacter pylori; GERD: Gastroesophageal reflux disease.